FAM122A, a new endogenous inhibitor of protein phosphatase 2A

Li Fan; Man-Hua Liu; Meng Guo; Chuan-Xi Hu; Zhao-Wen Yan; Jing Chen; Guo-Qiang Chen; Ying Huang

doi:10.18632/oncotarget.11698

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

FAM122A, a new endogenous inhibitor of protein phosphatase 2A

Li Fan, Man-Hua Liu, Meng Guo, Chuan-Xi Hu, Zhao-Wen Yan, Jing Chen, Guo-Qiang Chen and Ying Huang _

PDF | HTML | How to cite

Oncotarget. 2016; 7:63887-63900. https://doi.org/10.18632/oncotarget.11698

Metrics: PDF 2534 views | HTML 3785 views | ?

Abstract

Li Fan1, Man-Hua Liu1, Meng Guo2, Chuan-Xi Hu2, Zhao-Wen Yan2, Jing Chen1, Guo-Qiang Chen1,2, Ying Huang2

1Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

2Institute of Health Sciences, Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Correspondence to:

Ying Huang, email: [email protected]

Guo-Qiang Chen, email: [email protected]

Keywords: FAM122A, PP2A, ubiquitination, phosphatase activity, cell growth

Received: March 29, 2016 Accepted: August 24, 2016 Published: August 30, 2016

ABSTRACT

The regulation of the ubiquitously expressed protein phosphatase 2A (PP2A) is essential for various cellular functions such as cell proliferation, transformation, and fate determination. In this study, we demonstrate that the highly conserved protein in mammals, designated FAM122A, directly interacts with PP2A-Aα and B55α rather than B56α subunits, and inhibits the phosphatase activity of PP2A-Aα/B55α/Cα complex. Further, FAM122A potentiates the degradation of catalytic subunit PP2A-Cα with the increased poly-ubiquitination. In agreement, FAM122A silencing inhibits while its overexpression enhances cell growth and colony-forming ability. Collectively, we identify FAM122A as a new endogenous PP2A inhibitor and its physiological and pathophysiological significances warrant to be further investigated.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11698

Publication Alerts

Research Papers:

FAM122A, a new endogenous inhibitor of protein phosphatase 2A

Abstract